Effect of a novel anti-PD-1-proIL-2 bifunctional fusion protein on potent anti-tumor activity via PD-1 checkpoint inhibition and conditional IL-2R agonism. Prediction of immune-related adverse events ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback